Micellar Vitamin D Formulation for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Vitamin D pharmaceutical and nutraceutical preparations have limited absorption and bioavailability, requiring high doses for effective treatment of deficiencies, and are susceptible to photodegradation, limiting their shelf-life.
Innovation Solution
A pharmaceutical formulation comprising an aqueous dispersion of micelles encapsulating Vitamin D, formed from tocopherol polyethylene glycol such as D-a-tocopherol polyethylene glycol succinate, providing a water-soluble and bioavailable form for oral administration, with a dosage regimen including loading and subsequent daily doses to achieve and maintain adequate blood serum levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of Vitamin D are administered to achieve required blood serum levels, then the effectiveness of treatment is improved, but the risk of toxicity and side effects increases
Solution Approach 1:
The patent changes the physical and chemical parameters of Vitamin D by converting it into micellar structures with specific size ranges (20-50 nm). This parameter transformation fundamentally alters the absorption characteristics, enabling high bioavailability at low doses without reaching toxic thresholds
Solution Approach 2:
The patent segments Vitamin D into individual micellar units that can be independently absorbed. Each micelle acts as a discrete delivery vehicle, allowing precise control over dosage and absorption rate, thereby preventing toxicity while maintaining effectiveness
2Ease of operation
If oral preparations are used for Vitamin D supplementation, then the ease of administration is improved, but the bioavailability and absorption are reduced
Solution Approach 1:
The patent creates a composite structure where Vitamin D is encapsulated within micellar assemblies formed by amphiphilic molecules. This composite architecture combines the water-soluble exterior with the lipid-soluble Vitamin D core, enabling oral administration while achieving superior bioavailability through enhanced intestinal absorption
Solution Approach 2:
The patent fundamentally changes the solubility parameters of Vitamin D by incorporating it into micellar structures. The micelles present a hydrophilic exterior to aqueous environments while sequestering the lipophilic Vitamin D in their cores, enabling oral delivery with high absorption efficiency
3Ease of manufacture
If Vitamin D is formulated in traditional preparations, then the manufacturing simplicity is maintained, but the shelf-life is limited due to photodegradation
Solution Approach 1:
The patent employs micellar shells that encapsulate Vitamin D, providing a protective barrier against photodegradation. These flexible micellar structures shield the sensitive Vitamin D molecules from light exposure while remaining compatible with standard manufacturing processes
Solution Approach 2:
The micellar structure acts as an intermediary between Vitamin D and the external environment, particularly light. The micelle absorbs and dissipates photonic energy before it can damage the Vitamin D, extending shelf-life without complicating manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant increases in blood serum Vitamin D levels with lower doses compared to traditional preparations, demonstrating improved bioavailability and prolonged efficacy, effectively treating Vitamin D deficiencies without the need for high-dose injections.
Implementation Method 1
the micelles are formed of, and essentially consist of, a tocopherol polyethylene glycol such as D-α-tocopherol polyethylene glycol succinate
Implementation Method 2
an aqueous dispersion of micelles encapsulating said Vitamin D
Data Source
Figure 1
AI summary
A process for producing a formulation adapted for oral administration, wherein the pharmaceutical formulation comprises at least 1 000 IU per dosage form, and wherein the pharmaceutical formulation comprises, or consists of, an aqueous dispersion of micelles encapsulating said Vitamin D, and wherein the micelles are formed of, and essentially consist of, a tocopherol polyalkylene glycol.